
Sponsored by: Alumni Ventures
This week only, HTN readers are invited to join the Alumni Ventures Healthtech Syndicate, giving individual investors access to high-potential startup opportunities.
Join to get:
Curated deal flow of healthtech startups
Diligence materials and discussions
No cost, no commitment to join
Opportunity to invest only if a company excites you
Whether you’re looking to augment existing deal flow or are new to venture investing, you can enroll in < 3 minutes.
Reminder: HTN is not affiliated with Alumni Ventures and does not provide investment advice.
If you're interested in sponsoring the newsletter, let us know!
My reflection: Is now the time for Direct Primary Care?
It was interesting to see this week a PCP featured in The Free Press talking about their decision to launch their own Direct Primary Care (DPC) practice. This follows a Health Affairs article last week suggesting that the number of clinicians participating in DPC grew from ~4,000 to ~7,000 between 2018 and 2023. The Free Press article includes a heady title talking about practicing medicine “the way it should be done”:
It all has me curious about how much we’re talking about DPC in 2026 and whether it will exit the niche status it has occupied over the last few decades.
Like most “new models” in healthcare, DPC/concierge clinics are anything but new. The concept dates back at least 20 years to efforts like Qliance in the mid-2000s and concierge practices dating back to the 1990s. It’s not hard to see the conceptual appeal for an enterprising provider who is burnt out by the system. If you charge $3,000 per year for a membership, as the provider in the article above does, at 150 patients, you’re bringing in $450,000 in annual revenue. And that’s before you add in any other potential revenue streams, i.e., longevity stuff. That sounds pretty nice, right?
It seems there are three key potential tailwinds for DPC at the moment: 1. provider dissatisfaction with the current state of the healthcare system, 2. OBBB changes to federal tax laws so that DPC can be paid for out of HSAs, and 3. a growing public interest in preventive care/longevity. Any one of these seems meaningful; all three together could catalyze the market.
The key headwind for DPC has generally remained consistent over time — fewer people are willing to pay for DPC than proponents expect. This has been true for venture-backed models like Qliance, which shut down in 2017. It has also proven true for health system-backed efforts, like Spectrum Health’s STRIVE clinic. And it’s also been challenging for countless independent providers. Southdale Internal Medicine seems like a good example of this. Back in 2013, it was a practice that went DPC with five physicians, after being founded in 1982. Today, there is one provider left in what appears to be the remaining version of that practice. If you check out the website, it now highlights the benefits of being a fee-for-service practice(!!) that offers “better-than-concierge medicine for adults with no annual fee.” It’s a fascinating counterpoint to the broader industry narrative against fee-for-service medicine.
We discussed the DPC momentum on Slack this week, and Connor Allen brought up the example of Primary Health Partners in Oklahoma as an example of how these dynamics might be changing. That DPC practice has scaled to ~25 physicians across 10+ locations. Connor made a strong case for the opportunity to build ~$100 million DPC businesses in metro areas that are cash flow positive and generate strong margins. The crux of the conversation is the percentage of the people in a metro area who would flip to a DPC model. If you believe 5% - 7% of a metro would pay for DPC, I tend to agree with Connor that a meaningful business could be built in a market. Yet I also think that historically, this number has been challenging to hit for a variety of reasons. The question is whether the tailwinds above make it more feasible in today’s environment.
The willingness-to-pay issues are ultimately why I remain in the camp that DPC will continue being a niche offering moving forward, barring some much more meaningful regulatory change in how primary care is paid for in the US. That said, I also can’t blame a provider for wanting to test out if they can build a practice on their own terms, and some of them will be successful in doing so. Many will also not be successful, but such is the nature of choosing an entrepreneurial path.
I have a feeling that high-quality (however one chooses to define it) PCPs will be in greater demand than ever over the next few years, and that question of where those PCPs will decide to work is worth keeping an eye on.
This Week’s Poll Question
Given this audience is a relatively well-educated healthcare audience, I’m curious what DPC use trends look like in this audience:
Do you use a direct primary care / concierge primary care provider?
One Big Thing
CVS Health’s annual Investor Day highlights its pharmacy assets as the business charts a new path forward
CVS Health hosted its 2025 Investor Day on Tuesday AM, offering a good look at its various businesses. Overall, the market seemed to react well to the Investor Day, with the stock up another couple of percent. At a high level, here were the updates across the key business segments:
Aetna is getting back to target margins. Management and cultural change are driving a disciplined recovery across insurance businesses; 2025 was a good first step on the return to target markets
Care Delivery is early on a path back to profitability. Significant changes are underway in Oak Street to adjust to a post v28 world, while there are interesting opportunities in Signify and MinuteClinics around quality visits and primary care
PBM is navigating the changing environment. CVS feels well-positioned in the PBM world as it adjusts to market demands; thinks PBMs aren’t going anywhere despite the headlines
Specialty pharmacy is a key growth lever. A key growth opportunity for the business moving forward with the wave of pharma innovation ahead
Retail has done a 180. It is seeing a renewed sense of momentum as a key piece of the CVS story; although unclear how much of the recovery was driven by CVS activity versus competitor pullbacks
The most striking part of the session to me was that, while the overall components of the business remain largely the same, CVS has almost entirely shifted the business's overarching narrative. Going back to 2023, the narrative centered around CVS’s care delivery assets as the central piece of a thesis that the integration of CVS’s various businesses would result in significantly higher customer lifetime values.
Yet the challenges 2024 brought invited Wall Street skepticism about whether CVS could execute on that model.
What has emerged in its place in 2025 is a narrative centered on the strength of CVS’s pharmacy assets across its PBM, specialty, and retail businesses, while Aetna is getting back to target margins. Even as Aetna talks about getting back to target margins, the narrative centers around managing total cost of care via an integrated approach across medical and pharmacy. The care delivery narrative, while still taking up airtime as it attempts to get Oak Street back to profitability, is no longer the central part of the thesis.
The market seems to be reacting well to that new path forward, with CVS’s stock now up 70% over the last year. It strikes me as well-positioned to ride the coming wave of pharmacy innovation in this country, and this strategic shift seems well-timed on the early side of that wave.
✍ Going Deeper
Martin and I did a 2,000+ word write-up for HTN members here, if you’re interested in diving in further. Or if you prefer you can watch us discuss on the YouTube, here:
Chart of the Week
As Martin covered in his policy roundup this week, early CMS data suggests that ACA marketplace enrollment numbers are coming in quite hot, almost 12% ahead of last year at this time. Long-time ACA sage Charles Gaba dissected the trends well in this post, highlighting the numbers this year compared to last year:
Given the general predictions of a decline in the ACA population, it seems counterintuitive that enrollment numbers are running hot compared to last year. Perhaps all the uncertainty has prompted people to shop earlier in this year's enrollment window.
Still, if you look at the state-by-state breakdown in Gaba’s post, you’ll see some states like Georgia have a 70% increase year-over-year, while some states like Colorado have a 30% decrease.
Other Top Headlines
Highmark and BCBS Kansas City announced an affiliation under which Highmark would acquire BCBS KC's brand license. BCBS KC will remain a locally-governed not-for-profit, with Highmark viewing this affiliation as a potential gateway to other opportunities, per Modern Healthcare.
The Information reported that Open Evidence is raising $250 million in equity at a $12 billion valuation. This is on the heels of the rapid growth in OpenEvidence's advertising revenue — The Information reports that it is generating $12 million per month today, up 3x from August.
CMMI announced a new model this week called MAHA ELEVATE, designed to address chronic diseases by supporting services, including functional / lifestyle medicine interventions that Original Medicare doesn’t cover. The model will provide ~$100 million to fund up to 30 proposals for 3 years.
Texas Attorney General Ken Paxton filed an antitrust lawsuit against Epic this week, claiming its monopolistic and deceptive conduct has harmed Texans. In potentially related news, Paxton announced his intent to run for Senate last month. Brendan Keeler provided a nice summary of the lawsuit here, for those looking to go deeper.
Louisiana has had quite the Medicaid saga this week, announcing it would end contracts with Aetna and UnitedHealth for 2026. Aetna and UHC covered almost 500k people in the state, roughly 1/3 of the state’s Medicaid population. This move apparently came only two weeks after state lawmakers voted to extend these contracts. Apparently, PBM-related litigation drove the move, with Louisiana’s AG vaguely noting that both companies were not compliant with state law. Then, later in the week, Louisiana announced that it was reinstating Aetna’s contract, and only cancelling UHC’s contract for 2026.
In a big deal in the brokerage market, WTW is acquiring Newfront for up to $1.3 billion, with $1.05 billion up front and a contingent payment of up to $250 million. Newfront launched in 2017, and by 2020 it was worth over $500 million after raising $100 million to build a tech platform for brokerages. In 2021, it acquired ABD Insurance and Financial Services, with the combined entity valued at $1.35 billion. It then raised $200 million at a $2.2 billion valuation back in 2022.
Funding Announcements
Radial, a mental health care model providing access to treatments, raised $50 million.
Aradigm Health, a platform for cell and gene therapy, raised $20 million.
Lin Health, a virtual platform for chronic pain recovery, raised $11 million.
Origin Therapy, a pediatric therapy model, raised $2.6 million.
What I’m Reading
Medicare Will Pay for AI Heart Scans That Haven't Proven They Work by Greg Katz
A fascinating read from a few weeks ago on the merits of AI cardiac screening and what it implies for the promises of preventive screening. Read more
The 2025 PhysiciansAI Report by Offcall
The team at Offcall shared survey results from 1,000+ physicians across 106 specialties about AI in healthcare. It includes interesting data on adoption of various AI tools among other things. Read more
Comparing for-profit and not-for-profit health insurers: How capital and surplus are managed by Scott Jones and Bill Miller
A nice read on how for-profit and not-for-profit insurers manage capital differently. Read more
Medicare Could Have Saved $7.0 Billion in Spending on Select Services Subject to Fraud, Waste, and Abuse if MA Techniques Had Been Employed by Ruth Tabak, Eric Hammelman, and Sarah Box
A BRG team, sponsored by Elevance, wrote a white paper looking at how Traditional Medicare could have saved $7 billion on areas like skin substitutes. Given the political concerns expressed over WISeR, this is well worth a read. Read more
Featured Jobs
New Ventures Principal at Redesign Health, a role dedicated to their new joint venture and co-building partnership with Cedars-Sinai. Learn more.
Hybrid (LA)
Care Strategy & Operations (Lead / Director) at Sailor Health, a behavioral health platform for seniors, covered by Medicare. Learn more.
$125k - $185k | In-person (NYC)
Principal Product Engineer, Data Applications at Kairon Health, a value-based care platform for practice intelligence and performance. Learn more.
$170k - $200k | Hybrid (NYC)
Head of Operations at IntusCare, a platform supporting PACE programs. Learn more.
$180k - $200k | Remote
Director / Senior Director, Partnerships and Alliances at Innovaccer, a healthcare data infrastructure company. Learn more.
Hybrid (SF)
Contact us to feature roles in our newsletter.
Want to comment or share feedback?
If this newsletter was forwarded to you, subscribe here or see more from Health Tech Nerds.



